X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -79,199 | -37,450 | -101,167 | -93,867 | -88,696 |
| Depreciation Amortization | 1,277 | 796 | 419 | 513 | 10,257 |
| Accounts receivable | 497 | -1,070 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -2,979 | -286 | 1,234 | 3,425 | 1,166 |
| Other Working Capital | -2,576 | 2,675 | 344 | 5,736 | -1,498 |
| Other Operating Activity | -2,638 | -95,566 | 2,658 | 7,091 | 7,866 |
| Operating Cash Flow | $-85,618 | $-130,901 | $-96,512 | $-77,102 | $-70,905 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 104,674 | -60 | -103 | -615 |
| Purchase Of Investment | -63,388 | -57,134 | -16,823 | 0 | 0 |
| Sale Of Investment | 74,542 | 26,450 | 2,000 | 0 | 0 |
| Purchase Sale Intangibles | -3,000 | -7,000 | N/A | 0 | N/A |
| Other Investing Activity | -3,000 | -7,000 | 0 | 0 | 0 |
| Investing Cash Flow | $8,154 | $66,990 | $-14,883 | $-103 | $-615 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 20,000 | 22,500 | N/A | N/A |
| Debt Repayment | 0 | 0 | -2,064 | -795 | 0 |
| Common Stock Issued | 238,628 | 294 | 68,711 | 122,839 | 76,245 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -2,000 |
| Other Financing Activity | 0 | 0 | -631 | -4,814 | 0 |
| Financing Cash Flow | $238,628 | $20,294 | $88,516 | $117,230 | $74,245 |
| Exchange Rate Effect | 213 | -156 | 99 | -105 | -319 |
| Beginning Cash Position | 56,475 | 100,248 | 123,028 | 83,108 | 80,702 |
| End Cash Position | 217,852 | 56,475 | 100,248 | 123,028 | 83,108 |
| Net Cash Flow | $161,377 | $-43,773 | $-22,780 | $39,920 | $2,406 |
| Free Cash Flow | |||||
| Operating Cash Flow | -85,618 | -130,901 | -96,512 | -77,102 | -70,905 |
| Capital Expenditure | N/A | -326 | -60 | -103 | -615 |
| Free Cash Flow | -85,618 | -131,227 | -96,572 | -77,205 | -71,520 |